The Mesothelioma Center News – Page 28
-
news
Asbestos Exposure & BansGrowing allegations of asbestos-contaminated talc in various consumer products, coupled with historic approval of a new treatment for pleural mesothelioma, made 2020 a year… -
news
Research & Clinical TrialsStudy: Immunotherapy Vaccine for Mesothelioma Still Promising
The ONCOS-102 immunotherapy vaccine continues its move toward future, first-line standard of care treatment for malignant pleural mesothelioma, based upon the latest study follow-up… -
news
Research & Clinical TrialsLatest T-Cell Clinical Trial Opens for Mesothelioma Patients
Memorial Sloan Kettering Cancer Center in New York City has begun recruiting patients with pleural mesothelioma for its latest — and potentially most… -
news
Asbestos Exposure & BansCongress Fails to Vote on Asbestos Ban Legislation
The U.S. House of Representatives last week failed to advance once-promising legislation that effectively would have banned asbestos use, frustrating advocates once again. -
news
Legislation & LitigationJohnson & Johnson Will Pay $100M in Baby Powder Lawsuits
Pharmaceutical giant Johnson & Johnson has agreed to pay more than $100 million to settle more than a thousand lawsuits claiming its iconic talc-based… -
news
Research & Clinical TrialsGene Therapy Clinical Trial for Mesothelioma Moving Forward
A much-anticipated, phase III clinical trial studying the use of gene therapy to combat pleural mesothelioma cancer has made a promising start. Interest… -
news
Research & Clinical TrialsMesothelioma Trial to Test Cancer Vaccine with Immunotherapy
A research team at Oslo University Hospital in Norway has opened a mesothelioma clinical trial using the novel UV1 cancer vaccine alongside a… -
news
Asbestos Exposure & BansGeorgia-Pacific Pledges $1B to Bestwall Asbestos Trust Fund
Georgia-Pacific has pledged $1 billion to fund an asbestos trust for bankrupt affiliate Bestwall LLC, clearing the path to a settlement of longstanding liability… -
news
Research & Clinical TrialsNew Lung Cancer Trial Could Benefit Mesothelioma Patients
Pharmaceutical giant Merck has teamed up with Novocure to test its cornerstone immunotherapy, pembrolizumab (Keytruda), alongside Tumor Treating Fields. The new phase II… -
news
Research & Clinical TrialsImmunotherapy Combination Extends Mesothelioma Survival
Standard-of-care treatment for unresectable pleural mesothelioma cancer could be changing soon, sparked by a recently completed international study of a novel immunotherapy combination.